Rescindo Therapeutics Inc Newsroom - Profile and News Archive
Rescindo Therapeutics Inc. was founded in 2015 by Dr. Athanasios Maroglou and Dr. Nicholas Katsanis with an objective to discover and develop new drugs for children with rare genetic diseases. Using a novel approach that combines genetics, molecular biology, and high throughput use of model organisms, we accelerate the discovery of new therapies.
Together with our academic, private sector partners, and patient advocacy groups, we are working toward bringing new treatments for life-threatening disorders.
Engage with Rescindo Therapeutics Inc
Learn more online at: https://www.rescindotherapeutics.com/
Follow: | LinkedIn